Latest Forum Topics / Biosensors | Post Reply |
Is Biosensors a good buy?
|
|||||
starlene
Elite |
07-Jun-2013 06:45
|
||||
x 0
x 0 Alert Admin |
Yiming 2000,congras,Rowsley & Maxicash make $$$ liao..I just came back from my 13day trip to New Zealand...saw Rowsley soar again
|
||||
Useful To Me Not Useful To Me | |||||
yiming2000
Senior |
07-Jun-2013 02:06
|
||||
x 0
x 0 Alert Admin |
Everytime there is a share buyback, the book value goes up. The company is still raking in cash at a high profit margin.    Very cheap now at 1.16. It's a pity that I have reached my target limit of 40 lots otherwise, I would collect more shares.   |
||||
Useful To Me Not Useful To Me | |||||
|
|||||
New123
Elite |
06-Jun-2013 21:14
|
||||
x 0
x 0 Alert Admin |
just hv to be patience. U will be rewarded .
|
||||
Useful To Me Not Useful To Me | |||||
fortunecat
Member |
06-Jun-2013 16:47
|
||||
x 0
x 0 Alert Admin |
considering the bloodbath for STI this week, this is holding surprising well. will it start its climb to $2 soon (dreaming... )?   | ||||
Useful To Me Not Useful To Me | |||||
p_for_profit
Member |
06-Jun-2013 12:57
|
||||
x 0
x 0 Alert Admin |
yeah so weird!! where he got so many shares to sell??
|
||||
Useful To Me Not Useful To Me | |||||
|
|||||
New123
Elite |
05-Jun-2013 19:49
|
||||
x 0
x 0 Alert Admin |
don't worry too much. another 1,250,000  shares buy back by company it will soon move up.
|
||||
Useful To Me Not Useful To Me | |||||
alexmay
Veteran |
05-Jun-2013 17:39
|
||||
x 0
x 0 Alert Admin |
I like BIG but when I buy it drops, haizz!!! http://www.nextinsight.net/index.php/story-archive-mainmenu-60/919-2013/6940-cimb-underweights-reits-sias-ups-king-wans-target-to-42-cents    cash got plenty!!!  |
||||
Useful To Me Not Useful To Me | |||||
yiming2000
Senior |
05-Jun-2013 14:13
|
||||
x 0
x 0 Alert Admin |
Biosensors is piling up cash in excess of $500 million. Falling stock price reflects no support from market because of weak sentiment. Price keep dropping on low volume of 1 or 2 million shares. Not significant when company has 1.7 billion shares outstanding. Just hang in there.   |
||||
Useful To Me Not Useful To Me | |||||
|
|||||
Cookie
Member |
04-Jun-2013 20:12
|
||||
x 0
x 0 Alert Admin |
another 2mio bought back.. & price stil manage to fall... what can u say |
||||
Useful To Me Not Useful To Me | |||||
New123
Elite |
01-Jun-2013 14:06
|
||||
x 0
x 0 Alert Admin |
Yup! Think so too! pick up some on Fri .
|
||||
Useful To Me Not Useful To Me | |||||
rbgmauq
Member |
31-May-2013 19:55
|
||||
x 0
x 0 Alert Admin |
Eurocor GmbH, a group company of Opto Circuits (India) has entered into a licensing agreement for their Drug Eluting Balloon (DEB) technology and related intellectual property (IP) rights in relation to the treatment of both coronary and peripheral artery disease with Biosensors International Group, Ltd. . The technical indicator shows a buy with the 1.464 target price in six months.   http://sgx.stoxline.com/quote.php?s=b20 | ||||
Useful To Me Not Useful To Me | |||||
infancybird
Senior |
31-May-2013 19:14
|
||||
x 1
x 1 Alert Admin |
Three good news from mgt...1. daily share buy back again today at 1.949 of 735,000 shares  and 2.. Bio formed a licensing agreement with an India listed medical company to market its Eurocor DES under Biosensor trademark. This new stents is for heart as well as for lower limbs blocked arteries. These new DES will get CE mark in 6 weeks times. and 3. Today shorting activities  of Biosensor has almost ceased. Shortist has retreated for now , at least. I think the mgt is working much harder now(dividend, acquisition, share buy back) and hopefully they will enhance the stk value for their  shareholders in the near future. Certainly looking more optimistic.
|
||||
Useful To Me Not Useful To Me | |||||
|
|||||
infancybird
Senior |
31-May-2013 13:19
|
||||
x 0
x 1 Alert Admin |
FYI, there is a i-seller ( i stand for irritating) noticed by me to be the chief blacksheep selling Biosensor share for the last 1 years. He will appear everytime when there is mkt correction and will keep selling  to suppress the price to about < $1.20. I think the company knew his presence  and will counter his move with share buy back.  His motive is unclear.
|
||||
Useful To Me Not Useful To Me | |||||
New123
Elite |
31-May-2013 13:14
|
||||
x 1
x 1 Alert Admin |
with the support from Management buying back shares . Think short term price may hold and rise to my TP of $1.35 - $1.40.
|
||||
Useful To Me Not Useful To Me | |||||
yiming2000
Senior |
31-May-2013 12:55
|
||||
x 0
x 0 Alert Admin |
Looks like a lot of people here are vested and holding this stick. Let's hope price will rise from now on. |
||||
Useful To Me Not Useful To Me | |||||
raykee
Senior |
31-May-2013 09:33
|
||||
x 0
x 0 Alert Admin |
call buy but who is f is selling cheaply?
|
||||
Useful To Me Not Useful To Me | |||||
riclew
Member |
31-May-2013 08:24
|
||||
x 0
x 0 Alert Admin |
Target S$1.65  (Long Term: Out Perform)
Despite headwinds in FY3/13, BIG delivered satisfactory results. The next 12 months may see persistent challenges before things start to pick up. The stock's risk-reward proposition appears palatable, considering the big uplift in earnings beyond that period. 4Q13/FY13 core earnings were in line with our expectations, forming 23%/102% of our full-year estimates. We cut FY14 EPS by 7% for lower margin assumptions while shaving our SOP-based target price to S$1.65. We reiterate our Outperform rating as the positive financial effects from new products, better operations and M& A accretion are understated. 4Q13/FY13 core earnings were in line with our expectations, forming 23%/102% of our full-year estimates. We cut FY14 EPS by 7% for lower margin assumptions while shaving our SOP-based target price to S$1.65. We reiterate our Outperform rating as the positive financial effects from new products, better operations and M& A accretion are understated. Results in line but dividend a positive surprise  FY13's 15% revenue growth to US$336m was driven by a 35% jump in IVP sales, a result of organic growth, offset somewhat by a 29% decline in licensing revenue due to competition in Japan. The drop in licensing fee was drastic as 4Q13 was the worst showing in eight quarters (-13% qoq). There was lesser adverse FX impact on licensing revenue in this case, meaning that volume was less than stellar. Overall, product gross margin improved from 80% in FY12 to 84% in FY13. For the first time since its listing, BIG proposed to reward shareholders with dividends (2 US cents, 31% payout ratio).
|
||||
Useful To Me Not Useful To Me | |||||
riclew
Member |
31-May-2013 06:31
|
||||
x 0
x 0 Alert Admin |
Good good.. the dark knight rises.. | ||||
Useful To Me Not Useful To Me | |||||
Peter_Pan
Supreme |
31-May-2013 03:12
Yells: "did you order dunkin' donuts" |
||||
x 0
x 0 Alert Admin |
Quite a number of buy calls from analysts. | ||||
Useful To Me Not Useful To Me | |||||
topdog22
Senior |
31-May-2013 01:34
|
||||
x 0
x 0 Alert Admin |
EQUITY RESEARCH COMPANY UPDATE Oppenheimer & Co Inc. 85 Broad Street, New York, NY 10004 Tel: 800-221-5588 Fax: 212-667-8229 Ingrid Yin, Ph.D. 212-667-7194 Ingrid.Yin@opco.com Oppenheimer & Co. Inc. does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. See " Important Disclosures and Certifications" section at the end of this report for important disclosures, including potential conflicts of interest. See " Price Target Calculation" and " Key Risks to Price Target" sections at the end of this report, where applicable. Stock Price Performance Company Description The Biosensors International group of companies develops, manufactures and markets innovative medical devices for interventional cardiology and critical care procedures, and is headquartered in Singapore. May 29, 2013 CHINA/HEALTHCARE Stock Rating: OUTPERFORM 12-18 mo. Price Target SGD1.80 BIG:SP - SES SGD1.20 3-5 Yr. EPS Gr. Rate 10% 52-Wk Range SGD1.42-SGD1.03 Shares Outstanding 1,747.0M Float 1,060.0M Market Capitalization SGD2,047.2M Avg. Daily Trading Volume 2,507,340 Dividend/Div Yield NA/NM Book Value $0.27 Fiscal Year Ends Mar 2014E ROE 7.4 % LT Debt $277.3M Preferred NA Common Equity $1,248M Convertible Available No Biosensors International FY4Q13 Revenue Miss Due to Royalty Decline FY14 Guidance Encouraging SUMMARY Biosensors reported a mixed quarter. Revenue of $88.8M (+0.7% yoy) missed OPCO/ consensus estimates of $91M/$99.5M. FY2013 revenue of $336.2M (+15.1% growth) was basically in line with our estimate of $338.4M but missed consensus' $340M, dragged by 28.6% yoy decrease on royalty income. We actually think Biosensors' geographical diversification helped because China/Japan DES markets are both tough in FYQ4. Although increased operating expenses weakened profitability, gross margin improved significantly. Strong pipeline and clinical data could help BIG resume growth in FY14/15. With the stock trading at 12x our FY15E diluted EPS, we believe the valuation is compelling considering a 15% FY2014 revenue growth guidance. KEY POINTS ■ estimates of $91M/$99.5M, and net income of $29.6M (+8.9% yoy) missed OPCO/ consensus estimates of $29.8M/30.4M. The culprit was the 28.6% yoy decline on royalty income. Management expects flat royalty in 2014. Mixed Results. Revenue of $88.8M (+0.7% yoy) missed OPCO/consensus■ suffered from slower PCI volume growth, continuous pricing pressure from tenders, and more fierce competition. In Japan, 4Q13 was hurt by intense competition and negative forex impact, which we expect to persist in FY14. China and Japan. Biosensors strives to maintain market share in China, which■ company. DES balloons and stents in peripheral applications and BioMatrix NeoFlex launch could provide new growth points. Spectrum Dynamics and potential M& As should diversify BIG's product portfolio. We believe the market assigns little value to BioFreedom, which should drive growth starting FY14. Product Diversification Started. Biosensors is transitioning to a platform■ for FY2014. Favorable geographic/product mix should stabilize margins going forward. With the stock trading at 12x our FY15E diluted EPS, much lower than peer's 18.5x, we believe the valuation is compelling. Guidance and Updated Model. Management guided 15% yoy revenue growth■ subject security or securities may be sold pursuant to an exemption from state securities registration in the state in which the institution is located. This research report is intended for use only by institutions to which theInvestment Thesis Biosensors International, as an established international DES player that is aggressive in emerging markets, is propelling its leading position by providing competitive products with innovations. Based on our view of a promising China drug-eluting stent (DES) market growing at 10.7% from 2012 to 2017, we believe Biosensors is in a position to steadily take more share from others and keep a 15.5% revenue CAGR until 2015, higher than the China DES industry's growth. With estimated revenue/net income CAGRs of 15.5%/8%, we expect Biosensors to grow into one of the largest interventional cardiology device providers and a diversified med-tech company in the world. Our price target of SGD1.80 implies 18.4x our FY 15E EPS of SGD0.098 and 55% upside potential. Price Target Calculation We derive the fair value of SGD1.80 by using a DCF valuation, assuming a WACC of 9.5% and a terminal growth rate of 4.0% in 2017 on an estimated $136 million of free cash flow. Our price target implies 18.4x our FY15E EPS of SGD0.098/USD0.077 and 55% upside potential. The P/E multiple is in line with peer's 18.5x. Key Risks to Price Target Risks to the shares achieving our price target include: 1) delay of SFDA approval of BioMatrix Flex 2) competition 3) pricing erosion in major markets including Europe, Japan and China 4) negative results of clinical trials 5) lower than expected royalty payments from Terumo 6) cost Inflation and 7) unfavorable regulatory changes. Note: We see Biosensors, as a stock trading under $5, as speculative and appropriate for risk tolerant investors. Important Disclosures and Certifications Analyst Certification - subject securities, which are reflected in the ratings as well as in the substance of this report. The author certifies that no part of his/her compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in this research report. The author certifies that this research report accurately states his/her personal views about thePotential Conflicts of Interest: Equity research analysts employed by Oppenheimer & Co. Inc. are compensated from revenues generated by the firm including the Oppenheimer & Co. Inc. Investment Banking Department. Research analysts do not receive compensation based upon revenues from specific investment banking transactions. Oppenheimer & Co. Inc. generally prohibits any research analyst and any member of his or her household from executing trades in the securities of a company that such research analyst covers. Additionally, Oppenheimer & Co. Inc. generally prohibits any research analyst from serving as an officer, director or advisory board member of a company that such analyst covers. In addition to 1% ownership positions in covered companies that are required to be specifically disclosed in this report, Oppenheimer & Co. Inc. may have a long position of less than 1% or a short position or deal as principal in the securities discussed herein, related securities or in options, futures or other derivative instruments based thereon. Recipients of this report are advised that any or all of the foregoing arrangements, as well as more specific disclosures set forth below, may at times give rise to potential conflicts of interest. Important Disclosure Footnotes for Companies Mentioned in this Report that Are Covered by Oppenheimer & Co. Inc: Stock Prices as of May 29, 2013 Shandong Weigao Group (1066.HK - HKSE, HK$8.74, PERFORM) MicroPort Scientific Corp. (853.HK - HKSE, HK$6.15, PERFORM) Boston Scientific Corp. (BSX - NYSE, $9.22, PERFORM) Medtronic, Inc. (MDT - NYSE, $51.98, OUTPERFORM) Mindray Medical Int'l Ltd. (MR - NYSE, $41.39, OUTPERFORM) St. Jude Medical, Inc. (STJ - NYSE, $44.48, PERFORM) |
||||
Useful To Me Not Useful To Me |